FY2026 EPS Estimates for AngioDynamics Increased by Analyst

Key Points

• Zacks Research raised its FY2026 EPS estimate for AngioDynamics from ($0.26) to ($0.23) while maintaining a "Hold" rating; the consensus full-year estimate is ($0.19).
• Analyst sentiment is mixed—one Strong Buy, three Buy, one Hold and one Sell—with a consensus rating of "Moderate Buy" and an average target price of $18.67.
• AngioDynamics beat last quarter's expectations with EPS of ($0.07) (vs. a ($0.11) estimate) and revenue of $78.42M; the stock trades around $11.10 with a market cap of about $459M and a 12‑month range of $8.36–$13.99.

AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) - Investment analysts at Zacks Research raised their FY2026 earnings estimates for AngioDynamics in a research report issued on Thursday, April 23rd. Zacks Research analyst Team now expects that the medical instruments supplier will earn ($0.23) per share for the year, up from their prior forecast of ($0.26). Zacks Research currently has a "Hold" rating on the stock. The consensus estimate for AngioDynamics' current full-year earnings is ($0.19) per share. Zacks Research also issued estimates for AngioDynamics' Q4 2026 earnings at ($0.15) EPS, Q1 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.03) EPS and Q2 2028 earnings at ($0.03) EPS.

ANGO has been the topic of several other research reports. Freedom Capital upgraded shares of AngioDynamics to a "strong-buy" rating in a report on Monday, April 6th. Canaccord Genuity Group dropped their target price on shares of AngioDynamics from $18.00 to $16.00 and set a "buy" rating on the stock in a report on Monday, April 6th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of AngioDynamics in a report on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $18.67.

AngioDynamics Stock Performance

Shares of ANGO stock opened at $11.10 on Monday. AngioDynamics has a 12-month low of $8.36 and a 12-month high of $13.99. The firm's 50 day moving average is $10.82 and its 200 day moving average is $11.50. The stock has a market capitalization of $458.65 million, a P/E ratio of -14.80 and a beta of 0.43.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last issued its earnings results on Thursday, April 2nd. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative net margin of 10.01% and a negative return on equity of 4.66%. The company had revenue of $78.42 million for the quarter, compared to analysts' expectations of $76.77 million.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. State of Alaska Department of Revenue purchased a new position in shares of AngioDynamics during the 3rd quarter worth $25,000. Farther Finance Advisors LLC boosted its stake in shares of AngioDynamics by 146.4% during the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier's stock worth $26,000 after acquiring an additional 1,199 shares during the last quarter. Washington Trust Advisors Inc. purchased a new position in shares of AngioDynamics during the 3rd quarter worth $27,000. Kemnay Advisory Services Inc. purchased a new position in shares of AngioDynamics during the 4th quarter worth $27,000. Finally, State of Wyoming purchased a new position in shares of AngioDynamics during the 2nd quarter worth $31,000. Hedge funds and other institutional investors own 89.43% of the company's stock.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company's products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.